News
BLCO
16.95
+0.53%
0.09
Weekly Report: what happened at BLCO last week (0914-0918)?
Weekly Report · 09/21 09:54
Analysts Offer Insights on Healthcare Companies: Bausch + Lomb Corporation (BLCO) and Longeveron (LGVN)
TipRanks · 09/21 08:50
‘Crisis of Its Own Creation’: Activist JANA Blasts Cooper, Demands CEO Search
Benzinga · 09/18 15:54
Weekly Buzz: RARE, BAYRY Win Approvals; SION Cuts Jobs, GSK Deals; AZN, RHHBY Lead
NASDAQ · 09/18 14:44
3 Small-Cap Stocks That Concern Us
Barchart · 09/17 03:32
Bausch + Lomb Receives FDA Warning Letter Over Sterile Drug Manufacturing At Tampa Plant, Citing Inadequate Aseptic Controls And Persistent Microbial Contamination; Products Deemed Adulterated
Benzinga · 09/15 13:42
Needham Reiterates Hold on Bausch & Lombto Hold
Benzinga · 09/15 10:07
Tracking Carl Icahn's 13F Report - Q2 2026 Update
Seeking Alpha · 09/15 00:47
Weekly Report: what happened at BLCO last week (0907-0911)?
Weekly Report · 09/14 09:57
Bausch + Lomb Gains CE Mark For SeeLyra Femtosecond Laser
NASDAQ · 09/11 11:06
Bausch + Lomb Announces European CE Mark Approval Of SeeLyra; To Seek Approvals Around The World
NASDAQ · 09/11 10:24
Bausch + Lomb announces European CE Mark approval of SeeLyra
TipRanks · 09/11 10:15
How Investors Are Reacting To Bausch + Lomb (BLCO) Positive Lens Study
Simply Wall St · 09/09 12:25
Leerink bullish on Bausch + Lomb, initiates with an Outperform
TipRanks · 09/09 12:15
1 Cash-Producing Stock with Exciting Potential and 2 We Ignore
Barchart · 09/09 08:36
Weekly Report: what happened at BLCO last week (0831-0904)?
Weekly Report · 09/07 09:52
Bausch + Lomb (BLCO) Gains Clinical Backing As Investors Ask If The Valuation Case Holds
Simply Wall St · 09/05 14:23
Most and least shorted mid- to mega-cap healthcare stocks at the end of August
Seeking Alpha · 09/02 14:00
Bausch + Lomb publishes new research on en Vista Aspire IOLs
TipRanks · 09/02 11:10
Does Advancing First-in-Class Dry Eye and Pain Drugs Change The Bull Case For Bausch + Lomb (BLCO)?
Simply Wall St · 09/02 05:39
More
Webull provides a variety of real-time BLCO stock news. You can receive the latest news about Bausch + Lomb Corporation through multiple platforms. This information may help you make smarter investment decisions.
About BLCO
Bausch + Lomb Corporation is an eye health company. It operates through three segments: Vision Care, Pharmaceuticals, and Surgical. Vision Care segment includes both a contact lens and a consumer eye care business that consists of contact lens care products, over-the-counter eye drops and eye vitamins. Pharmaceuticals segment consists of generic pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. Surgical segment consists of medical device equipment, consumables, instruments and technologies for the treatment of cataracts, corneal and vitreous and retinal eye conditions, which includes delivery systems, phacoemulsification equipment and other surgical instruments and devices for cataract surgery. Its brands consist of PreserVision, Biotrue, Artelac, Alaway, Mioclear, Ocuvite, ScoutPro, XIIDRA, Vyzulta, Lotemax, Prolensa, Minims, INFUSE, and many more.